Streetwise Reports' Article Archives — Current Month (10)
AI Healthcare Stock Has Bullish Setup, Expert Says (04/22/2024)
Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy.
PDUFA Date Coming Up for U.K. Biopharma (04/22/2024)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
Biopharma's New Drug for COPD Likely to be Approved (04/22/2024)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
New AI Solutions Set To Transform Medical Education and Clinical Practice (04/19/2024)
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).
Analyst Says Pharma Co. Has No True Competitor (04/19/2024)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
LA Biotech's Lower Revenue Will Be Short Lived (04/17/2024)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
Healthcare Co. Welcomes Possible AI Funding Effort in Canada (04/09/2024)
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.
Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out (04/08/2024)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
Co. Adding 500 Patients to Its Mental Health Care Platform (04/03/2024)
This Canada-based health care technology firm is profitable and growing. Learn more about it here.
Analyst Encouraged by ON Gov's Decision To Sustain Fees (04/02/2024)
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
